Noxopharm Ltd.ASX: NOX

Noxopharm receives $1.4 million R&D tax incentive rebate

· Issued by Noxopharm Ltd. via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Noxopharm Ltd. has received a rebate from the Australian Government's R&D Tax Incentive scheme, which will support its ongoing clinical studies and technology platform development. The rebate will specifically aid the SOF-SKN extension study for patients with cutaneous lupus erythematosus and enhance the broader Sofra technology platform.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Noxopharm receives $1.4 million R&D tax incentive rebate Highlights • $1.4 million refund received via Australian Government R&D Tax Incentive scheme • Support for SOF-SKN™ extension study and Sofra™ technology platform Sydney, 12 November 2026: Australian clinical-stage biotechnology...

Noxopharm Ltd. on 6ix

Earlier from Noxopharm

Later from Noxopharm

All Noxopharm news releases